Last reviewed · How we verify
Albiglutide liquid auto-injector
Albiglutide liquid auto-injector is a GLP-1 receptor agonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Type 2 diabetes mellitus.
Albiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and lower blood glucose in patients with type 2 diabetes.
Albiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and lower blood glucose in patients with type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Albiglutide liquid auto-injector |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Albiglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and promotes satiety, contributing to improved glycemic control and modest weight loss. The liquid auto-injector formulation provides a convenient once-weekly subcutaneous delivery mechanism.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Hypoglycemia
Key clinical trials
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus (PHASE3)
- Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects (PHASE4)
- Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albiglutide liquid auto-injector CI brief — competitive landscape report
- Albiglutide liquid auto-injector updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Albiglutide liquid auto-injector
What is Albiglutide liquid auto-injector?
How does Albiglutide liquid auto-injector work?
What is Albiglutide liquid auto-injector used for?
Who makes Albiglutide liquid auto-injector?
What drug class is Albiglutide liquid auto-injector in?
What development phase is Albiglutide liquid auto-injector in?
What are the side effects of Albiglutide liquid auto-injector?
What does Albiglutide liquid auto-injector target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Albiglutide liquid auto-injector vs similar drugs
- Pricing: Albiglutide liquid auto-injector cost, discount & access